| Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic … J Kang, RJ Eudy‐Byrne, J Mondick, W Knebel, G Jayadeva, ... British Journal of Clinical Pharmacology 86 (11), 2274-2285, 2020 | 15 | 2020 |
| Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors O Yin, AJ Wagner, J Kang, W Knebel, H Zahir, M van de Sande, WD Tap, ... The Journal of Clinical Pharmacology, 2020 | 8 | 2020 |
| MECHANISM OF ACTION, PHARMACOKINETIC PROFILES, AND PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS DIFFER BETWEEN CIPAGLUCOSIDASE ALFA/MIGLUSTAT AND ALGLUCOSIDASE ALFA IN LATE … F Johnson, J Kang, J Mondick, S Sitaraman, Y Wasfi, M Goldman, ... MUSCLE & NERVE 66, S89-S89, 2022 | 2 | 2022 |
| Population pharmacokinetic analysis of pexidartinib in healthy subjects and patients with tenosynovial giant cell tumor (TGCT) or other solid tumors O Yin, J Kang, W Knebel, H Zahir, M van de Sande, WD Tap, ... Tenth American Conference on Pharmacometrics (ACoP10), 2019 | 2 | 2019 |
| Population pharmacokinetic analysis for comparison of pexidartinib exposure in Asian and non-Asian patients CC Lin, J Guo, WD Tap, AJ Wagner, S Stacchiotti, JH Lee, X Wang, ... Connective Tissue Oncology Society (CTOS) Annual Meeting, 2019 | 1 | 2019 |
| Plasma total GAA protein PK profiles differ between cipaglucosidase alfa/miglustat and alglucosidase alfa FK Johnson, J Kang, J Mondick, S Sitaraman, Y Wasfi, M Goldman, ... Molecular Genetics and Metabolism 135 (2), S63, 2022 | | 2022 |
| Web-based Software for Real-time Simulation-Assisted Trial Design in Alzheimer’s Disease D Polhamus, J Kang, J Rogers, M Gastonguay The Journal of Prevention of Alzheimer’s Disease (JPAD), 2014 | | 2014 |
| Model-Based Meta-Analysis for Virologic Response Rate in Hepatitis C Virus (HCV) Clinical Trials J Kang, KT Baron, DG Polhamus, JL French, MR Gastonguay Clinical Pharmacology & Therapeutics 93 (S1), S5, 2013 | | 2013 |
| Population Model-based Estimates of Genotype-dependent CYP2C9 Mediated Flurbiprofen Oral Clearance and In vivo Inhibition Constant (Ki) for Fluconazole Interaction J Kang, RC Brundage, V Kumar, TS Tracy The 41st Annual meeting of American College of Clinical Pharmacology (ACCP), 2012 | | 2012 |
